Rituximab therapy for autoimmune haematological diseases

Wilma Barcellini, Alberto Zanella

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Autoimmune haematological diseases are characterized by the production of antibodies against blood proteins or cells, and comprise primary immune thrombocytopenia, autoimmune haemolytic anaemia, acquired haemophilia, and thrombotic thrombocytopenic purpura. Current treatments for these disorders include corticosteroids, cytotoxic drugs and splenectomy, which may be associated with significant systemic toxicity and/or morbility. B cells play a key role in both the development and perpetuation of autoimmunity, since they produce autoantibodies but also function as antigen-presenting cells, and release immunomodulatory cytokines. Rituximab, an anti-CD20 monoclonal antibody that specifically depletes B cells, may be an effective treatment strategy for patients with autoimmune disorders. This article reviews data of the literature, showing that patients with autoimmune haematological diseases can respond to rituximab irrespective of age and number or type of prior treatments. These data suggest that rituximab provides an effective and well-tolerated treatment option for these conditions.

Original languageEnglish
Pages (from-to)220-229
Number of pages10
JournalEuropean Journal of Internal Medicine
Volume22
Issue number3
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Hematologic Diseases
Autoimmune Diseases
B-Lymphocytes
Autoimmune Hemolytic Anemia
Idiopathic Thrombocytopenic Purpura
Hemophilia A
Splenectomy
Antigen-Presenting Cells
Therapeutics
Autoimmunity
Autoantibodies
Antibody Formation
Blood Proteins
Blood Cells
Adrenal Cortex Hormones
Monoclonal Antibodies
Cytokines
Rituximab
Pharmaceutical Preparations

Keywords

  • Acquired haemophilia
  • Autoimmune haemolytic anaemia
  • Cold haemagglutinin disease
  • Primary immune thrombocytopenia
  • Rituximab
  • Thrombotic thrombocytopenic purpura

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Rituximab therapy for autoimmune haematological diseases. / Barcellini, Wilma; Zanella, Alberto.

In: European Journal of Internal Medicine, Vol. 22, No. 3, 06.2011, p. 220-229.

Research output: Contribution to journalArticle

@article{2d11bb8b74e849c798a3e39a3bccc371,
title = "Rituximab therapy for autoimmune haematological diseases",
abstract = "Autoimmune haematological diseases are characterized by the production of antibodies against blood proteins or cells, and comprise primary immune thrombocytopenia, autoimmune haemolytic anaemia, acquired haemophilia, and thrombotic thrombocytopenic purpura. Current treatments for these disorders include corticosteroids, cytotoxic drugs and splenectomy, which may be associated with significant systemic toxicity and/or morbility. B cells play a key role in both the development and perpetuation of autoimmunity, since they produce autoantibodies but also function as antigen-presenting cells, and release immunomodulatory cytokines. Rituximab, an anti-CD20 monoclonal antibody that specifically depletes B cells, may be an effective treatment strategy for patients with autoimmune disorders. This article reviews data of the literature, showing that patients with autoimmune haematological diseases can respond to rituximab irrespective of age and number or type of prior treatments. These data suggest that rituximab provides an effective and well-tolerated treatment option for these conditions.",
keywords = "Acquired haemophilia, Autoimmune haemolytic anaemia, Cold haemagglutinin disease, Primary immune thrombocytopenia, Rituximab, Thrombotic thrombocytopenic purpura",
author = "Wilma Barcellini and Alberto Zanella",
year = "2011",
month = "6",
doi = "10.1016/j.ejim.2010.12.016",
language = "English",
volume = "22",
pages = "220--229",
journal = "European Journal of Internal Medicine",
issn = "0953-6205",
publisher = "Elsevier B.V.",
number = "3",

}

TY - JOUR

T1 - Rituximab therapy for autoimmune haematological diseases

AU - Barcellini, Wilma

AU - Zanella, Alberto

PY - 2011/6

Y1 - 2011/6

N2 - Autoimmune haematological diseases are characterized by the production of antibodies against blood proteins or cells, and comprise primary immune thrombocytopenia, autoimmune haemolytic anaemia, acquired haemophilia, and thrombotic thrombocytopenic purpura. Current treatments for these disorders include corticosteroids, cytotoxic drugs and splenectomy, which may be associated with significant systemic toxicity and/or morbility. B cells play a key role in both the development and perpetuation of autoimmunity, since they produce autoantibodies but also function as antigen-presenting cells, and release immunomodulatory cytokines. Rituximab, an anti-CD20 monoclonal antibody that specifically depletes B cells, may be an effective treatment strategy for patients with autoimmune disorders. This article reviews data of the literature, showing that patients with autoimmune haematological diseases can respond to rituximab irrespective of age and number or type of prior treatments. These data suggest that rituximab provides an effective and well-tolerated treatment option for these conditions.

AB - Autoimmune haematological diseases are characterized by the production of antibodies against blood proteins or cells, and comprise primary immune thrombocytopenia, autoimmune haemolytic anaemia, acquired haemophilia, and thrombotic thrombocytopenic purpura. Current treatments for these disorders include corticosteroids, cytotoxic drugs and splenectomy, which may be associated with significant systemic toxicity and/or morbility. B cells play a key role in both the development and perpetuation of autoimmunity, since they produce autoantibodies but also function as antigen-presenting cells, and release immunomodulatory cytokines. Rituximab, an anti-CD20 monoclonal antibody that specifically depletes B cells, may be an effective treatment strategy for patients with autoimmune disorders. This article reviews data of the literature, showing that patients with autoimmune haematological diseases can respond to rituximab irrespective of age and number or type of prior treatments. These data suggest that rituximab provides an effective and well-tolerated treatment option for these conditions.

KW - Acquired haemophilia

KW - Autoimmune haemolytic anaemia

KW - Cold haemagglutinin disease

KW - Primary immune thrombocytopenia

KW - Rituximab

KW - Thrombotic thrombocytopenic purpura

UR - http://www.scopus.com/inward/record.url?scp=79955996011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955996011&partnerID=8YFLogxK

U2 - 10.1016/j.ejim.2010.12.016

DO - 10.1016/j.ejim.2010.12.016

M3 - Article

VL - 22

SP - 220

EP - 229

JO - European Journal of Internal Medicine

JF - European Journal of Internal Medicine

SN - 0953-6205

IS - 3

ER -